AUSTIN, Texas, Nov. 22 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today that it has been awarded U.S. Patent No. 7,125,706, titled “An Improved Method for the Production and Purification of Adenoviral Vectors.” This patent covers purified adenoviral compositions or preparations without limitation to the type of adenovirus, the use or application of the adenovirus and without limitation as to how the adenovirus is produced. This patent complements two previously issued U.S. patents in Introgen’s intellectual property portfolio directed to the production of adenoviral vectors.
“This patent adds considerably to Introgen’s extensive adenovirus intellectual property portfolio,” said David L. Parker, PhD., J.D., Introgen’s senior vice president for Intellectual Property. “With this patent, we have complemented and enhanced the coverage of Introgen’s previously announced U.S. patents that cover the commercial production of adenoviruses in general, and without regard to the gene they carry, if any, or their use.”
This patent is of particular importance in that it covers adenovirus of commercial scale quantity and purity, regardless of whether the adenovirus is used as a delivery system for therapeutic genes, used directly as a therapeutic agent, used as a vaccine or vaccine component or simply used for research and development purposes.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Certain statements in this press release that are not strictly historical may be “forward-looking” statements, which are based on current expectations and entail various risks and uncertainties. Such forward-looking statements include, but are not limited to, those relating to Introgen’s future success with patent protection for its process and development of adenoviral vectors for use in its clinical development program. There can be no assurance that Introgen will be able to commercially develop gene-based drugs, that necessary regulatory approvals will be obtained or that any clinical trials or studies undertaken will be successful or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgen’s operations and business environment, including, but without limitation, Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, Introgen’s dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, Ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
